Clinical and therapeutic profile of patients with hyperthyroidism in an outpatient endocrine clinic at a university hospital in southern Brazil
DOI:
https://doi.org/10.11606/issn.2176-7262.rmrp.2021.178114Keywords:
Hyperthyroidism, Graves’disease, Nodular goiterAbstract
Introduction: Hyperthyroidism results from the serum elevation of thyroid hormones, secondary to hyperfunction of the thyroid gland. The main causes are Graves' disease (DG) and Toxic Nodular Goiters (BNT). Objectives: Evaluate the clinical profile and therapeutic modalities applied in patients diagnosed with hyperthyroidism followed up at a University Hospital in Southern Brazil. Methods: Observational, cross-sectional and descriptive study, including patients diagnosed with hyperthyroidism by DG and BNT; epidemiological, clinical, laboratory and treatment data were collected. Results: Most patients were referred by primary care and had been using antithyroid drugs (DAT). The age variable obtained showed a statistically significant difference between the etiologies of DG and BNT; in both, there was a predominance of incidence in females. DG showed a higher frequency of signs and symptoms of thyrotoxicosis, while BNT showed more signs and symptoms of compression. There was remission of the disease in 23.2% of patients with DG treated with DAT; in 23.2% of the patients, low-dose methimazole was maintained for more than 36 months and in 16.1%, definitive treatment was performed. In BNT, definitive therapies were preferred, mainly thyroidectomy, in 27.5% of patients. Low doses of methimazole for more than 36 months were also used in BNT in 22.5% of patients. Conclusion: Hyperthyroidism is a heterogeneous disease, from initial clinic to therapy, among its most prevalent etiologies. There was a tendency to prioritize long-term drug therapies with low doses, both in DG and BNT.
Downloads
References
Kim M, Ladenson P. Tireoide. In: Goldman L, Ausinello DA. Goldman Cecil Medicina. 24 ed. Vol 2. Rio de Janeiro: Elsevier; 2014. p. 1665-80.
Ross DS, Burch HB, Cooper DS et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26(10):1343-421. doi: 10.1089/thy.2016.0229.
De Leo S, Lee SY, Braverman LE. Hyperthyroidism. Lancet. 2016; 388(10047):906-18. doi: http://dx.doi.org/10.1016/S0140-6736(16)00278-6
Graf H. Manuseio do bócio uninodular e multinodular tóxico. In Vilar L, editor. Endocrinologia clínica. 6 ed. Rio de Janeiro: Guanabara Koogan; 2016. p. 327-34.
Maia AL, Scheffel RS, Meyer ELS, et al. Consenso Brasileiro de diagnóstico e tratamento do hipertireoidismo: recomendações do Departamento de Tireoide da Sociedade Brasileira de Endocrinologia e Metabologia. Arq Bras Endocrinol Metab. 2013; 57(3):205-32. doi: 10.1590/S0004-27302013000300006.
Burch HB, Cooper DS. Antithyroid drug therapy: 70 years later. Eur J of Endocrinol. 2018; 195(5):261-274. doi: http://doi.org/10.1530/EJE-18-0678
Yeo CP, Khoo DH, Eng PH, Tan HK, Yo SL, Jacob E. Prevalence of gestational thyrotoxicosis in Asian women evaluated in the 8th to 14th weeks of pregnancy: correlations with total and free beta human chorionic gonadotrophin. Clin Endocrinol (Oxf). 2001; 55(3):391-8. doi: 10.1046/j.1365-2265.2001.01353.x.
Brent GA. Clinical practice. Graves’ disease. N Engl J Med. 2008; 358(24): 2594-605. doi.: 10.1056/NEJMcp0801880.
Pontes AAN, Adan LF, Costa ADM, et al. Prevalência de Doenças da Tireoide em Uma Comunidade do Nordeste Brasileiro. Arq Bras Endocrinol Metab. 2002; 46(5):544-9. doi: http://dx.doi.org/10.1590/S0004-27302002000500008.
Doubleday AR, Sippel RS. Hyperthyroidism. Gland Surg. 2020; 9(1):124-135. doi:10.21037/gs.2019.11.01.
Brasil. Ministério da Saúde. Universidade Federal do Rio Grande do Sul. Protocolos de encaminhamento da atenção básica para atenção especializada v.1 - Endocrinologia e Nefrologia. Brasília: Ministério da Saúde; 2015. Disponível em http://bvsms.saude.gov.br/bvs/publicacoes/protocolos_atencao_basica_atencao_especializada_endocrinologia.pdf.
Hussain YS, Hookham JC, Allahabadia A, et al. Epidemiology, management and outcomes of Graves’disease – real life data. Endocrine. 2017; 56(3): 568-78. doi: 10.1007/s12020-017-1306-5.
Guevara-Linares X, Jasso-Huamán L, Ramírez-Vela RM, et al. Características clínicas, demográficas y perfil tiroideo de los pacientes hospitalizados por hipertiroidismo en un hospital general. Rev Med Hered. 2015; 26(3):141-6. Disponível em: http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1018-130X2015000300002&lng=es.
Kahaly GJ, Bartalena L, Hegedus L, et al. 2018 European Thyroid Association Guideline for the Management of Grave’s Hyperthyroidism. Eur Thyroid J. 2018;7(4):167-86. doi: 10.1159/000490384.
Sharma A, Stan MN. Thyrotoxicosis: Diagnosis and Management. Mayo Clin Proc. 2019; 94(6):1048-64. doi: https://doi.org/10.1016/j.mayocp.2018.10.011.
Yang H, Negishi K, Otahal P, Marwick TH. Clinical prediction of incident heart failure risk: a systematic review and meta-analysis. Open Heart. 2015; 2(1):e000222. doi: 10.1136/openhrt-2014-000222.
De Filippis EA, Sabet A, Sun MR, Garber JR. Pemberton's sign: explained nearly 70 years later. J Clin Endocrinol Metab. 2014; 99(6):1949-54. doi: 10.1210/jc.2013-4240.
Törring O, Tallstedt L, Wallin G, et al. Graves’ hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine — a prospective, randomized study. J Clin Endocrinol Metab 1996; 81(8):2986-93. doi.: https://doi.org/10.1210/jcem.81.8.8768863.
Villagelin D, Romaldini JH, Santos BR, et al. Outcomes in Relapsed Graves’Disease Patients Following Radioiodine or Prolonged Low Dose of Methimazole Treatment. Thyroid. 2015; 25(12):1282-90. doi: 10.1089/thy.2015.0195.
Azizi F, Ataie L, Hedayati M, et al. Effect of long-term continuous methimazole treatment of hyperthyroidism: comparison with radioiodine. Eur J Endocrinol. 2005; 152(5):695–701. doi: https://doi.org/10.1530/eje.1.01904.
Lauberg, P, Berman DC, Andersen S, et al. Sustained Controlo of Graves’ Hyperthyroidism During Long-Term Low-Dose Antithyroid Drug Therapy of Patients with Severe Graves’ Orbitopathy. Thyroid. 2011; 21(9):951-6. doi: 10.1089/thy.2011.0039.
Stumpf MAM, Schrut GCA, Ramthun M, Onuma S, Osternack HECG. Methimazole-induced agranulocytosis and sepsis: was thyroid storm present or just being mimicked? Acta Endocrinol (Buchar). 2019; 15(4):522-525. doi: 10.4183/aeb.2019.522.
Azizi F, Taikyar MA, Madreseh E, et al. Treatment of toxic multinodular goiter: Comparason of radiodine and long-term methimazole treatment. Thyroid. 2019; 29(5):625-30. doi: 10.1089/thy.2018.0397.
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Rafael Antonio Parabocz1 Parabocz, Renata Soares Carvalho, Gianna Carla Alberti Schrut, Ana Claudia Garabeli Cavalli Kluthcovsky4 Kluthcovsky, Matheo Augusto Morandi Stumpf
![Creative Commons License](http://i.creativecommons.org/l/by/4.0/88x31.png)
This work is licensed under a Creative Commons Attribution 4.0 International License.